Avacopan

CHEMBL3989871 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
581.6 g/mol
LogP
7.2
Phase
4

A selective complement C5a receptor antagonist taken by mouth that dampens the inflammatory response driven by the complement system in certain autoimmune vasculitides such as ANCA-associated vasculitis. It allows dose reduction of steroids while maintaining disease control.

Berat Molekul

581,6000 g/mol

LogP

7,20

TPSA

61,40 Ų

Lipinski RO5

Gagal

Area Terapeutik

Mekanisme Kerja

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F

InChI

InChI=1S/C33H35F4N3O2/c1-20-12-15-25(19-27(20)33(35,36)37)39-31(41)26-10-6-18-40(32(42)29-21(2)7-5-11-28(29)34)30(26)22-13-16-24(17-14-22)38-23-8-3-4-9-23/h5,7,11-17,19,23,26,30,38H,3-4,6,8-10,18H2,1-2H3,(H,39,41)/t26-,30-/m0/s1

Molecular Formula

C33H35F4N3O2

HBD / HBA

2 / 7

Ikatan yang Dapat Dirotasi

6

Atom Berat

42

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A selective complement C5a receptor antagonist taken by mouth that dampens the inflammatory response driven by the complement system in certain autoimmune vasculitides such as ANCA-associated vasculitis. It allows dose reduction of steroids while maintaining disease control.

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Yes, Avacopan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989871. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 49841217. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.